

Special Issue

HIV and Drug of Abuse

Message from the Guest Editors

Due to the lack of a vaccine against HIV, precautions and anti-HIV therapies are the only available solutions. It is now well documented that drugs of abuse, in addition to deteriorating the central nervous system (CNS) function, accelerate the natural course of HIV disease progression. Significant progress has been made in uncovering the underlying molecular mechanism that different drugs of abuse influence to modulate HIV gene expression, transmission, and associated disease progression. Nevertheless, the effects of drug abuse on HIV are multifaceted and largely unclear, and further investigations are required in order to understand the in-depth molecular mechanisms and how they can be used for therapeutic benefits. Studies to understand these mechanisms may reveal new drug targets and open up new avenues for better pharmaceutical interventions in HIV-infected drug abusers.

Guest Editors

Dr. Mudit Tyagi

Center for Translational Medicine, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA

Dr. Adhikarimayum Lakhikumar Sharma

Centre for Translational Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA

Deadline for manuscript submissions

closed (30 April 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/89254

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).